公与妇伦日本理片_日本猛少妇色XXXXX猛叫_强壮的公次次弄得我高潮A片日本_日本无码人妻丰满熟妇5G影院_日本无码人妻丰满熟妇5G影院_日本欧美久久久久免费播放网

Shanghai King-cell Biotechnology Co. Ltd. was established in Shanghai Jinshan Industrial Zone on April 19, 2017. (hereinafter referred to as "King-cell Biotech") is a national high-tech enterprise dedicated to the R&D, production and sales of innovative vaccines. After years of precipitation and accumulation, the company has three major technology platforms: virus reverse genetic manipulation technology platform, vaccine evaluation and detection method development platform and industrialization development technology platform, with the development ability of differentiated innovative varieties, which can realize the rapid directional development of strains used in the production of innovative vaccines, establish a reasonable verification system for safety and efficacy evaluation, and implement industrial transformation of products with clinical value. The company has obtained the first clinical notice of domestic commercial rabies vaccine (chicken embryo fibroblasts) and recombinant live attenuated mumps vaccine (Fgenotype), and will continue to complete the research and development of other vaccines to meet market demand.

King-cell Biotech Industrialization Base covers an area of 72.4 acres, with a total construction area of nearly 100,000 square meters, a total investment of 15+ billion yuan, and an annual output of 30 million vaccine production capacity after completion.

In December 2022, the company was nominated for the list of "2022 China Pharmaceutical Cutting-edge Innovation Force", and passed the ISO14001:2015 and ISO45001:2018 environmental and occupational health and safety system certifications in the same year. In May 2023, it was awarded the "2023 Future Healthcare 100 China Innovative Biopharmaceutical List", and in September 2023, it was selected as the most promising enterprise (seed enterprise) of Ernst & Young Fudan. In November 2023, it was awarded the title of the most valuable enterprise in China's pharmaceutical industry in 2023.

Enterprise mission: to improve the level of human health and benefit mankind

Corporate vision: Committed to becoming an influential high-quality innovative vaccine company

The core values of the enterprise: practice promises, be kind to others, create with ingenuity, and benefit mankind